July 2012 By Karyn Kaplan According to the Universal Declaration of Human Rights and subsequent treaties, all people have a fundamental right to the highest attainable standard of health, as well as a right to the benefits of scientific progress…
December 2012 By Tracy Swan It is difficult to be anything other than dazzled by astounding cure rates of up to 100% from a multitude of interferon-free hepatitis C virus (HCV) clinical trials presented at the American Association for the…
December 2012 Update - Cure rates presented at the American Association for the Study of Liver Diseases (AASLD) July 2012 By Tracy Swan and Karyn Kaplan Dedicated to Michael Carden A fabulous, kind, brilliant, and hilarious friend and colleague 1971–2012…
Selected updates to this chapter will be posted below prior to the 2013 edition of the Pipeline Report. Feburary 2013 Update Additional clinical trials in the Research Toward a Cure/Therapeutic Vaccines/Gene Therapies categories: Genetically Modified Peripheral Blood Stem Cell Transplant…
JULY 2012 By Polly Clayden NOTE: a postscript section at the end of this article includes periodic updates since publication in June 2012. In June 2010, the WHO and UNAIDS launched Treatment 2.0, a strategic approach to the achievement of…
By Polly Clayden NOTE: a postscript section at the end of this article includes periodic updates since publication in June 2012. In the past year—since our last Pipeline Report—there has been a flurry of activity in pediatric antiretroviral drug development…
July 2012 By Simon Collins NOTE: a postscript section at the end of this article includes periodic updates since publication in June 2012. Updates from CROI 2013. (March 2013) at the end of this article. INTRODUCTION Two aspects of antiretroviral…
July 2012 By Polly Clayden and Mark Harrington In nine countries, we enrolled 1763 couples in which one partner was HIV-1–positive and the other was HIV-1–negative; 54% of the subjects were from Africa, and 50% of infected partners were men…
July 2018 by Bryn Gay Simpler Rapid, Point-of-Care Hepatitis C Diagnostics: Are We There Yet?1 To increase treatment rates and make a dent in the epidemic by 2030, countries need to scale up access to affordable, simple, rapid diagnostics, ensuring…
July 2018 Annette Gaudino HCV TREATMENT PIPELINE: THE DEFERRED DREAM OF TREATMENT FOR ALL Generic combinations of direct-acting antivirals (DAAs), including sofosbuvir/daclatasvir show bioequivalence compared to originators with equivalent sustained virological responses (SVR). Both sofosbuvir/daclatasvir and sofosbuvir/ravidasvir demonstrate SVR rates…